Our Company Resources

Resources

Articles

IND-Enabling Preclinical Development: Engineering the Bridge from Discovery to First-in-Human

Analytical Validation Across Phases: Balancing Speed, Cost, and Compliance

De-Risking Drug Product Quality Through Strategic Extractables & Leachables Assessment

Redefining Stability Protocols for Modern Small Molecule APIs

Stability and Scalability in Cell Line Development for Commercial Biologics

Accelerating Formulation Paths to First-in-Human: Why Fit-for-Purpose is the Smart Strategic Choice

From Model to Marker: An Integrated Framework for Advancing IPF Drug Development

SPR Across the Spectrum: Enabling Discovery of Small and Large Molecules

Late-Stage Modification of Peptides: Advanced Strategies for CRDMO Success

REACH: Simplifying the Complex World of Chemical Safety

Platform vs. Bespoke: Choosing the Right Early Formulation Strategy for Your Molecule

Challenges and Solutions in Cell Line Development for Biologics

High-Throughput Electrophysiology for Drug Screening and Discovery

TMT Labeling for Optimized Sample Preparation in Quantitative Proteomics

Revolutionizing new drug discovery- Harnessing AI ML Tools

Flow Chemistry vs. Batch Processes

Solutions for Mitigating Challenges in Recombinant Protein Production

Propelling Glioblastoma Research: Aragen Bioscience’s Orthotopic Model Solutions

Preclinical Model of Post – Incisional Pain for Efficacy Testing of Novel Therapeutics

Manual Whole-Cell Patch Clamp Assay for Screening NCE’s Against Voltage Gated Ion-Channels

Clinically relevant preclinical model of CFA-Induced inflammatory pain

Exploring Molecular Interactions Through Surface Plasmon Resonance

Experimental λ-Carrageenan-induced inflammatory pain model for testing novel analgesics

A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells

Accelerating the regulatory approval process of biosimilars by leveraging precise and reliable PK data and PD biomarker data

Streptozotocin-induced Diabetic Peripheral Neuropathic Pain Model Developed at Aragen

Experimental Chronic Constriction Injury (CCI)- induced Neuropathic Pain Model Aragen Life Sciences

Experimental pain models at Aragen Life Sciences – Spinal Nerve Ligation (SNL) Model of Neuropathic Pain

Drug-Protein Interaction: Limitless Application of Mass spectrometry in Target Engagement, Intact Mass and Peptide Mapping Analysis.

Automation to miniaturize In vitro assays to achieve superior and cost-efficient results

Targeted Protein Degradation

Pharmacokinetic study of Salbutamol through nose only exposure in CD-1 male mice

Aragen’s Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics

Industry Leading Hybridoma Technique for Accelerated Antibody Discovery

Covalent Drugs – Advantages, Challenges, And Opportunities

Mitigating CMC issues through Aragen’s holistic approach to developability assessment

Aragen’s Preclinical Oncology Capabilities – Tumor Imaging

Preclinical evaluation of Novel drug candidates against SLE in NZB/W F1 mouse models

Aragen’s Oncology solutions: Accelerate your cancer therapeutics development

RSV Challenge Model for anti-RSV therapy

Cell Line Development at Aragen: Research cell banks in 5 months

Effect of Methylprednisolone on the Systemic lupus erythematosus (SLE) in murine models

DSS-induced IBD Mouse Model for preclinical drug screening

Cell Line Development at Aragen; Accelerating speed to IND

Brochures

Expedite Your Success with Aragen’s Comprehensive IND-Enabling Services

Lipid Chemistry Capabilities

Analytical Solutions

Process Development Services

Resin Recycling Studies

Agro-Chemical Formulation Solutions: Transforming Ideas into Effective Products

Combat Nitrosamine Challenges with Comprehensive Analytical Solutions

Your partner for timely, accurate and high-quality preclinical efficacy studies

Navigating Recombinant Protein Production– Leveraging Aragen’s Multifaceted Expression Systems

Gene to GMP Fully integrated or customized options

Modalities for Mechanistic Exploration in Agrochemical Solutions

Paclitaxel-induced Peripheral Neuropathic Pain Model Developed at Aragen

Comprehensive Services for Immersive Corrosion Testing of Metals and Alloys Across a Wide Spectrum of Test Subjects

Aragen Cell Line Development Solutions for Biologics CHO CLD Platforms

Comprehensive Solutions for Animal Health Biologics

Comprehensive In-Vitro Microbial Kill Rate Studies for screening antimicrobial agents

Genetic and Alternative Toxicity Testing for Compound Screening, Derisking and Selection

Oligonucleotides

Phosphonamidite

Specialized Services in Custom Peptide Synthesis (Solution Phase)

Comprehensive DoE capabilities for Synthesis, Process Development and Manufacturing of Novel Chemical Entities (NCE’s)

Comprehensive GLP regulated Ecotoxicology Services

Comprehensive and Regulated “Developmental and Reproduction Toxicology (DART)” studies

Preclinical Safety Evaluation and Clinical Bioanalysis Services for Vaccines

Intox Safety Assessment

Nonclinical Safety Assessment of New Biological Entities (NBEs)

Process Safety, Dust Explosion Testing Capabilities

Material Science

Aragen Overview

Nonclinical Safety Assessment of New Chemical Entities (NCE)

Aragen protein science solutions: Industry leading upstream and downstream capabilities

Your Partner for Chemocatalysis Solutions

Highly Potent Active Pharmaceutical Ingredients (HPAPIs)

Biocatalysis Solutions

Flow Chemistry

Analytical Solutions Laboratory

Targeted Protein Degradation Solutions

Aragen’s quantitative proteomics sampling capabilities: Accurate and Reproducible Workflows

Pharmacokinetics (PK)/ Pharmacodynamics (PD) and Mechanistics solutions in Ellegaard Göttingen Minipigs

Comprehensive Characterization of Biologics

Aragen’s Preclinical Oncology Capabilities

Preclinical Evaluation of new Antifibrotics in IPF Rodent Models

Pharmacokinetic (PK) solutions in large animals

Formulation Solutions

Discovery Biology Solutions

ADME – DMPK Solutions

Extractables and Leachables Solutions

In Vitro Pharmacology Solutions

In Vivo Pharmacology Solutions

Nitrosamine Impurity Detection and Quantification

TOXVIT – Aragen In Vitro Toxicology Solutions

ICP-MS

Protein Analytics Solutions

PeptAR_x – Aragen’s Integrated Peptide Platform

API and Intermediates

Integrated Drug Discovery Solutions

Discovery Chemistry Solutions

Developability and Analytics Solutions

Contract Manufacturing Solutions

Integrated Cell Line Development Solutions

Small Molecule Process R&D and Manufacturing Solutions

Amylin Liver NASH (AMLN)

Case Studies

Cysteine-Directed ADC Bioconjugation with Controlled DAR and Functional Validation

Comprehensive Bioanalytical Strategy for ADC Therapeutics

Obesity-Induced Sarcopenia: Translational Mouse Model for Muscle & Metabolic Therapies

From Challenge to Success: High-Purity Membrane Protein Production Across Multiple Classes

Developing a Reliable BCMA‑Expressing CHO‑K1 Cell Line to Accelerate the Discovery of Next‑Generation Cancer Therapeutics

Scalable Production of Unique Pseudoproline and Dmb Dipeptides for Efficient SPPS

Advancing Peptide Therapeutics Through Efficient Synthesis of Unnatural Amino Acids

Optimized SPR-Based Screening of RNA-Targeting Small Molecules

Enhancing Palatability in a Dual-API Oral Formulation for Canine Health

Strategic Optimization of Small Molecule Inhibitors for Enhanced Tumor Growth Inhibition

Transforming Biologics Manufacturing Through Smart Upstream Process Intensification

Enhancing Crystallization Control with In-Line PAT for Scalable Manufacturing

Exploring PROTAC Permeability: Comparative Insights Across Different Cell Lines

Reporter Cell Lines for Immuno-Oncology Drug Discovery: Targeting T-Cell Activation

Leveraging Surface Plasmon Resonance for Characterizing Ternary Complexes

Scalable Production of High-Purity Nanobodies Using Yeast Expression System

Redefine In silico Predictions with High-throughput LC-MS/MS LogD Analysis

Unravelling Immunological Depths: Exploring Oxazolone-induced Delayed-Type Hypersensitivity Model

Unlocking Insights: A Translational Mouse Model for Non-Genetic Heterotopic Ossification

A Preclinical Efficacy Study using Diet induced Obesity Mice Model

Designing an optimal and scalable protocol for formulating a 40% emulsifiable concentrate for a systemic insecticide

Developing a thermodynamically stable microemulsion with fine droplet size for delivering a highly lipophilic drug with limited intestinal permeability

Elevating Purity Levels: Racemizing Pharmaceutical Products in Advanced Flow Microreactors

Modelling Targeted Protein Degraders (TPDs) Utilizing Computational and Medicinal Chemistry Approaches

Flow Chemistry

A robust and scalable strategy to develop monodisperse Nanosuspension formulation for a poorly soluble drug substance

A robust and scalable strategy to develop amorphous solid dispersion formulation for a poorly soluble drug substance

Comprehensive Preclinical Development Program for a COVID mRNA Vaccine

Expression, in vivo Maturation and Tag-less Purification of a Recombinant Protein

An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)

On-demand Webinars

Reproductive and developmental toxicity studies for small molecules, large molecules, biologics, and vaccines

Advanced In Vivo Efficacy Models for Preclinical Success

Accelerating Small Molecule Drug Product Development

Advancing Biologics Development at Aragen

Advances in HPAPI Development and Regulatory Strategy

Enhancing mAb Platform Process using Membrane Affinity Chromatography for FIH Molecules

PROTACs: Breaking Boundaries in Drug Discovery

Process Development of New Chemical Entities — Overcoming Challenges of Safety and Quality for a Seamless Technology Transfer

Enabling Clinical Development of Poorly Soluble Molecules Through Formulation Solutions

Accelerating Biologics Development to Medicines: Key Drivers of Success

Development of Covalent Drugs with New Emerging Technologies

Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models

Driving Better Titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform

The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development

Upstream Process Development for Better Yield and Product Quality

Amorphous Solid Dispersion — An Ideal Formulation Approach to Improve Developability of Poorly Soluble Molecules

Posters

Cell & Protein Sciences

From Binding to Degradation : Multiscale Insight into PROTAC-Mediated Protein Targets

Advanced Peptide Synthesis Strategies for High-Purity, Complex modification and Scale-Up: A CRO Perspective

Therapeutic Impact of an ALK5 Inhibitor Across Multiple Preclinical Fibrosis Models

Enhancing mAb platform process using Membrane chromatography (Affinity/Protein-A, using Sartobind Rapid A) for FIH molecules with focus on Optimizing cost and Accelerating timelines

In vitro phototoxicity validation study

Decoding the Conformational Plasticity of Ternary Complexes for Protacs’ Differential Activity

Comparative Analysis: Responses to Immunotherapy

In vitro/In vivo Correlation of Permeability

Blood Brain Permeability and CNS Bioavailability

Column Head Loading in SFC

Phenotypic Characterization of Bleomycin-Induced Pulmonary Fibrosis Model

Reliable and Reproducible Preclinical Rodent Models of MAS

Whitepapers

Particle Engineering Meets Formulation: Why Integration Matters

Cyclic Peptides in Drug Discovery: Enabling Better Design

Phase-Appropriate CMC Strategies for Complex Small Molecules: Integrating Drug Substance and Drug Product to Avoid Late-Stage Surprises

Integrated In vivo Oncology Studies for Predictive Preclinical Efficacy Outcomes

GLP-Compliant Toxicology Studies: The Cornerstone of Vaccine Safety and Regulatory Approval

High-Content Screening: Accelerating Smarter Drug Discovery Decisions

Surviving Early Development: Why Integrated DS–DP Programs Reduce CMC Risk

Zero 483 Quality Culture & Inspection Readiness

Peptide Bioanalysis Using LC-MS/MS: Challenges and Strategies

Phosphoramidite Chemistry: The Engine Behind Oligonucleotide Innovation

Transposase Technologies: Optimizing Cell Line Development for Consistent and High-Yield Biomanufacturing

Regulatory-Ready Nitrosamine Analysis: Advanced LC–MS/MS Solutions for Confident Compliance

Beyond Containment: Innovations in HPAPI Manufacturing for Next-Generation Oncology Therapeutics

Rigorous Toxicology Assessments in Nutraceutical Safety: Meeting FDA and EFSA Guidelines

Nano-Size Engineering Solutions for Poorly Soluble Compounds: A CRDMO Perspective

PROTAC-Based Degrader Antibody Conjugates: Combining Protacs with Monoclonal Antibodies for Precision Therapy

From Molecular Pharmaceutics to Scalable Manufacturing: CRDMO Expertise in Spray Dried Dispersions

Pharmacokinetic Assessment and Anti-Drug Antibodies Assessment of GLP-1 Receptor Agonists

Enhancing Biopharmaceutical Manufacturing with Single-Use Bioreactors: A Transformative Solution for CRDMO Operations

Targeted CNS Drug Delivery: Stereotaxic Animal Model and ICV Administration

Preclinical Evaluation of new Antifibrotics in IPF Rodent Models

Preclinical evaluation of vaccines and antivirals in RSV challenge SCID mouse models

Preclinical evaluation of vaccines and antivirals in RSV challenge in BALB/c Mouse models

A Novel Cell-based Screening Assay for Cholesterol Biosynthetic Pathway Inhibition Using the RapidFire HTMS Platform

A Highly Reproducible In Vivo Model for Bleomycin-Induced Lung Fibrosis in Mice to Evaluate Drugs for the Treatment of Idiopathic Pulmonary Fibrosis

Pharmacokinetic Strategies in CNS Drug Discovery

Preclinical Models of Immune oncology for CART-cell Therapeutics Development

Preclinical Evaluation of Vaccines and Antivirals in RSV Challenge Rodent Models

Preclinical Evaluation of new Antifibrotics in NASH-Induced Fibrosis Models

Preclinical Evaluation of new Antifibrotics in Corona mouse Virus-Induced Fibrosis Model

Blogs

Analytical Method Development Services

Method Transfer De-Risks in Integrated DS–DP: When and How to Avoid Inter-Site Transfers

Ensuring Biosafety of Genetically Engineered Crops: Meeting the Standards

Accelerating Cell Line Development for Biologics and Biosimilars

Comprehensive E-Fate and Metabolism Studies for Agrochemicals and Metabolites

What is Cell Line Development?

Formulation as a Development Lever: Immediate-release and Controlled- release in Early-Stage Drug Development

The Role of Green Chemistry in Driving Success in Chemical Innovations

Optimizing Pharmaceutical Processes and Enhancing Biological Experimental Design Efficiency with Design of Experiments Methodology

The Essential Role of Analytical Chemistry in the Pharmaceutical Industry

Overcoming Challenges in Chemical Engineering during Pharmaceutical Scale-Up

Innovative Solutions: Overcoming Chemical Synthesis Hurdles in the Global CDMO Landscape

Navigating Growth: Challenges and Opportunities in the Small Molecule CDMO Sector

The Synergy of Services: How CDMOs Drive Innovation in Medicinal Chemistry?

CDMOs: Pioneering Partnerships in Immuno-Oncology Drug Development

Streamlining Small Molecule Drug Development: The Advantages of Integrated CDMOs

Maximizing Efficiency: How High-Throughput Screening Services Drive Drug Discovery

The Rise of High Potent APIs: Trends, Technologies, and Manufacturing Best Practices

CDMO Innovations: Advancing Pharma Manufacturing with Chemical Development Solutions From Early To Late Phase